Market Trends of Allergy Immunotherapy Industry
Subcutaneous Immunotherapy (SCIT) is Expected to Witness Growth Over the Forecast Period
Subcutaneous immunotherapy (SCIT), is the most commonly used and most effective form of allergy immunotherapy and it is the only treatment available that actually changes the immune system, making it possible to prevent the development of new allergies and asthma. SCIT is a unique therapy for allergic disease as it provides symptomatic relief while modifying allergic disease by targeting the underlying immunological mechanism. Its efficacy and safety have been demonstrated in the treatment of asthma, allergic rhinitis/rhinoconjunctivitis, and hypersensitivity to stinging insects in multiple controlled clinical trials. SCIT is administered by injection, and refers to what is commonly known as an 'allergy shot'. It is the standard medication for allergen desensitization and provides symptomatic relief for patients with allergic rhinitis and asthma.
The high efficacy and cost-effectiveness of SCIT is the major driver for the segment. For instance, as per the study published in August 2021, by the Journal of Allergy and Clinical Immunology: In Practice, SCIT is much more effective than SLIT drops or tablets in controlling symptoms of allergic rhinitis. Therefore, high efficacy of SLIT indicates that the demand for the product is anticiapted to increase, thereby surging the segment growth over the forecast period.
In June 2021, Stallergenes Greer announced that Alustal, its subcutaneous allergen immunotherapy (SCIT) solution, was available in Italy and Spain following the full resumption of SCIT production in Antony (France).
North America is Expected to Hold the Largest Market Share over the Forecast Period
North America is expected to dominate the overall allergy immunotherapy market, over the forecast period. The growth is due to factors such as increasing cases of allergies and increasing awareness of allergy treatment. For instance, according to the report published by International Food Information Council in May 2022, in the United States, about 32.0 million people have reported having food allergies, and each year around 200,000 people seek emergency medical care due to food allergies. It also reported that food allergies were common among youths, with about one in every 13 children being diagnosed with a food allergy in the United States and around 40.0% of children with food allergies being allergic to more than one food. Such instances are anticipated to propel the demand for allergy immunotherapy in this region.
Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and increasing cases of allergies in the United States are some of the factors driving the growth of the allergy immunotherapy market in the country. For instance, in January 2023, ALK announced that the US FDA approved ODACTRA (House Dust Mite Allergen Extract) Tablet for Sublingual Use for the treatment of house dust mite (HDM)-induced allergic rhinitis in persons ages 12 through 17.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.
